Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Men with negative MRI after negative biopsy do not harbour prostate cancer

17 Nov 2020

A negative magnetic resonance imaging (MRI) following an initial negative MRI-guided biopsy is unlikely to lead to clinically significant prostate cancer and repeat biopsy, suggests a study. However, repeat MRI-guided biopsy is needed when lesions are seen on follow-up MRI.

A total of 2,716 men were identified, of whom 733 had a negative initial MRI-guided biopsy. Of these, 73 underwent follow-up MRI-guided biopsy. Participants had a median age of 64 years (interquartile range [IQR], 59–67) and prostate-specific antigen density of 0.12 ng/ml/cc (IQR, 0.08–0.17). Baseline Prostate Imaging Reporting and Data System (PI-RADS) score was 3 in 74 percent of men.

Seventeen of 73 participants (23 percent) were diagnosed with clinically significant prostate cancer at follow-up MRI-guided biopsy (median, 2.4 years; IQR, 1.3–3.6). Clinically significant prostate cancer was also found in 17 of 53 men (32 percent) when follow-up MRI showed a lesion (PI-RADS 3). However, cancer was not detected (0/10; p<0.01) when follow-up MRI was negative (PI-RADS <3).

Notably, more than half (54 percent) of men with PI-RADS 5 at follow-up MRI-guided biopsy were diagnosed with clinically significant prostate cancer.

This study included all men with a negative initial MRI-guided biopsy who underwent at least one more MRI-guided biopsy due to continued suspicion of clinically significant prostate cancer between September 2009 and July 2019. Biopsies were MRI-ultrasound fusion with targeted and systematic cores. The investigators targeted regions of interest from initial MRI and other new regions of interest at follow-up MRI-guided biopsy.

“MRI-guided biopsy which reveals no cancer may impart reassurance beyond that offered by ultrasound-guided biopsy. However, follow-up of men after a negative magnetic resonance imaging guided biopsy has been mostly by prostate-specific antigen testing and reports of follow-up tissue confirmation are few,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.